Astria Therapeutics
Astria Therapeutics develops therapies for allergic and immunological diseases, with its lead program STAR-0215 aimed at preventing hereditary angioedema attacks. The company is headquartered in Boston, MA, and is listed on the NASDAQ under the ticker symbol ATXS.
Services
Astria Therapeutics is dedicated to developing therapies for allergic and immunological diseases. Their efforts focus on the research and development of therapeutic agents aimed at providing long-lasting relief and treatment for conditions like hereditary angioedema (HAE) and atopic dermatitis. The company is committed to addressing unmet medical needs through innovative and durable solutions. They are also actively seeking to in-license additional therapeutics that have the potential to further their mission.
Products
Astria Therapeutics' lead product is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein designed to prevent hereditary angioedema (HAE) attacks. The product has demonstrated promising results in the ALPHA-STAR Phase 1b/2 trial, showing a significant reduction in monthly HAE attack rates by 90-96% for up to six months. STAR-0215 is designed for administration once every three to six months. In addition, the company is developing STAR-0310, a monoclonal antibody OX40 antagonist that is currently in preclinical development for treating atopic dermatitis, aiming to provide durable efficacy with dosing every two to three months.
History
Founded in 2008, Astria Therapeutics is an innovative biotechnology company that has been incorporated under the laws of the State of Delaware. The company, headquartered in Boston, Massachusetts, went public on June 26, 2015, and is listed on the NASDAQ Global Market under the ticker symbol ATXS. Since its inception, Astria Therapeutics has been committed to addressing unmet medical needs in the field of allergic and immunological diseases.
Headquarters
Astria Therapeutics is headquartered at 75 State Street, Suite 1400, in Boston, Massachusetts, 02109. The centrally located headquarters allows them to be in proximity to key partners, collaborators, and the vibrant biotechnology community that Boston offers. The company's headquarters serves as the hub for their operations, research, and development activities.
Corporate Governance
Astria Therapeutics upholds a commitment to diversity, equity, and inclusion (DE&I), fostering a culture of openness, respect, and collaboration within the company. They have raised significant capital from leading life science investors to fund their research and development programs. The company’s fiscal year ends on December 31.